Generalized Periodic Discharges: Nonconvulsive Status Epilepticus or Diffuse Encephalopathy-A Case Comparison.

J Clin NeurophysiolApr 2, 2026 (epub)
Case ReportNeurology

Chanawee Hirunpattarasilp, Joshua Edmondson, Daniel Wood et al.

✦ AI-curated · Sources linked

Case in brief

The report describes nonconvulsive status epilepticus (NCSE) with coma in a patient whose neurotoxicity was attributed to ceftriaxone. The EEG showed generalized periodic discharges (GPDs), a pattern often seen in comatose, critically ill patients with NCSE. The authors compared this presentation with NCSE without coma in a patient with chronic focal epilepsy, whose altered awareness was characterized by dialepsis: eyes open and posture retained, but unresponsive with amnesia. The comparison highlights that GPDs in coma may be an epiphenomenon, whereas dialepsis is considered a clinical manifestation of epileptiform activity.

What made this case unusual

The report contrasts ceftriaxone-associated NCSE with coma and GPDs against NCSE without coma in chronic focal epilepsy, emphasizing that similar epileptiform EEG activity may have different clinical significance.

Diagnostic / clinical pearl

Interpret GPDs in the clinical context: in comatose patients they may be an epiphenomenon rather than the direct cause of coma; dialepsis in NCSE without coma is described as a manifestation of epileptiform discharges.

Source

Published in J Clin Neurophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.